Nektar Therapeutics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Nektar Therapeutics said Q3 2026 was a transformative quarter, with its global Phase 3 ZENITH-AD studies initiated and its Phase 3 alopecia areata study on track to start in December, earlier than originally planned.
- The ZENITH-AD program comprises 3 pivotal studies enrolling approximately 1,500 patients, while ZENITH-AA is planned to enroll approximately 850 patients; together, the ZENITH program will enroll approximately 2,400 patients ages 12 and older.
- At the EADV conference, Nektar presented RESOLVE-AD maintenance and biomarker findings and alopecia areata off-treatment data; the biomarker substudy found early changes in regulatory T-cell markers and multiple inflammatory pathways that were correlated with later clinical improvement.
- Nektar ended Q3 2026 with approximately $953 million in cash and investments and no debt.
- Q3 2026 non-cash royalty revenue was $8.5 million, R&D expense was approximately $44 million, G&A expense was approximately $25 million, and non-cash interest expense was approximately $6 million.
- Nektar reported a Q3 net loss of approximately $56 million, or $1.63 basic and diluted net loss per share.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello, and thank you for standing by. Welcome to the Nektar Therapeutics Third Quarter 2026 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. Please be advised that today's conference call is being recorded. I would now like to hand the conference over to Vivian Wu from Nektar Investor Relations to kick things off.
Please go ahead. Thank you, Crystal, and good afternoon, everyone.
Thank you for joining us today. On today's call, you will hear from Howard Robin, our President and Chief Executive Officer, Dr. Mary Tagliaferri, our Chief Medical Officer, Dr. Jonathan Zalevsky, our Chief Research and Development Officer, and Linda Rubinstein, our Chief Financial Officer. Before we begin, I would like to remind you that we will be making forward-looking statements regarding our business, including statements related to the therapeutic and commercial potential and development plans for rezpegaldesleukin, the timing and execution of clinical trials, expectations for clinical data and regulatory filings, potential strategic partnering activities, financial guidance, and other statements regarding the future of our business. Because forward-looking statements relate to the future, they are subject to uncertainties and risks that are difficult to predict, many of which are outside of our control.
For a discussion of these risks and uncertainties, please refer to our filings with the SEC, including our most recent Form 10-K and subsequent filings. We undertake no obligation to update these forward-looking statements except as required by law. A live webcast and replay of this call will be available on the Investor Relations section of our website at nektar.com. With that, I'll turn the call over to Howard.
Thank you, Vivian. Thank you to everyone for joining us this afternoon. Q3 was a transformative quarter for Nektar as we advanced REZPEG into phase III studies. Building on its compelling phase II results across two key immune derm indications, we initiated a comprehensive phase III plan for REZPEG in both atopic dermatitis and alopecia areata. Our global phase III studies in atopic dermatitis have started, and our phase III study in alopecia areata is on track to start in December, earlier than was originally planned. As we said last quarter, we anticipate our first top-line data readouts for the atopic dermatitis studies will be in the summer of 2028. In the U.S. alone, over 31 million people are estimated to have eczema. The U.S. market for treatments for this chronic disorder is expected to grow to over $30 billion by 2033.
Now, in spite of a number of approved systemic therapies to treat patients with moderate to severe atopic dermatitis, only one in four patients today receive a systemic treatment. Atopic dermatitis is a highly heterogeneous disease, meaning the biology driving the underlying disease state can be complex and can vary significantly from one patient to another. The current approved biologics target one single inflammatory pathway, specifically the type 2 inflammatory pathway, and mostly through IL-13 cytokine blocking. In order to ensure we have treatments that can address the needs of all patients with atopic dermatitis, it is necessary to have novel mechanisms that target the heterogeneous nature of this disease. Importantly, today we know that at least half of patients on an existing biologic report inadequate control of their atopic dermatitis for this reason.
To that end, REZPEG's novel Treg mechanism offers a critically important therapeutic modality for patients and one that is currently missing from the treatment armamentarium. We know from our market research that physicians are looking for different mechanisms of action than those that are already approved. Rather than blocking a single downstream inflammatory pathway, REZPEG's first-in-class Treg approach selectively expands the immune cells to restore immune balance. In other words, we're addressing the underlying inflammatory drivers rather than simply controlling the symptoms of the disease. JZ will talk more about some of the important translational work we have from REZPEG AD, which demonstrates the unique profile we have for REZPEG. In the commercial landscape in atopic dermatitis, we've already seen clear evidence of the demand for a mechanism outside of IL-13. NEMLUVIO, which is an IL-31 cytokine blocker, gained a label in atopic dermatitis only in combination with topicals.
Based on recent U.S. claims data, NEMLUVIO is capturing at least 10% of new treatment starts about seven quarters into launch. In fact, since its launch, DUPIXENT has lost these new-to-brand patients starts, going from an 81% share of starts in 2024 to 65% today, with more than half of the share that DUPIXENT has lost going to novel MOAs. Physician willingness to start patients on a novel agent outside of DUPIXENT reaffirms for us the market research we've conducted for REZPEG, indicating an opportunity for REZPEG in first-line as well as second-line treatments. With the recent setbacks in the OX40 class, we believe there are no agents in mid-to-late-stage development that address the underlying heterogeneity of disease in atopic dermatitis in the way that REZPEG addresses it, by targeting the full range of inflammatory pathways. This gives REZPEG a truly unique competitive position.
In our research, approximately 90% of surveyed dermatologists indicated that they would consider starting a patient on REZPEG before starting a patient on another biologic or a JAK inhibitor. This underscores the dermatologist community's receptiveness to try novel MOAs as a first-line treatment. With regulatory agency alignment, we're advancing our phase III program to support a broad label, including first-line use in patients new to biologics and JAK inhibitors, as well as second-line use in previously treated patients. In alopecia areata, REZPEG has a unique opportunity to offer a compelling first-line therapy as compared to the existing approved JAK inhibitor class. Oral JAK inhibitors require daily dosing and carry box safety warnings and laboratory monitoring requirements. The market, according to Decision Resources Group, is forecasted to reach approximately $5.2 billion by 2033.
Mary will talk more about our phase III programs in atopic dermatitis and alopecia areata in a few moments. At the recent EADV conference, we presented multiple oral presentations for REZPEG, which Mary will also review in a bit. Beyond our two lead dermatology indications, we believe REZPEG continues to offer broad potential in other autoimmune indications. The phase II study in new-onset type 1 diabetes, sponsored and funded by TrialNet, is ongoing, and we currently estimate that we could have data from the first cohort of patients in late 2027. As I said last quarter, we are planning to initiate a new signal-seeking trial for REZPEG in another immune indication, and Mary will talk more about our specific plans and that opportunity. With that, I will turn the call over to Mary.
Thank you, Howard, and good afternoon, everyone. As stated earlier, we had a significant presence at the EADV conference with three separate oral sessions for REZPEG. We had two presentations for REZOLVE-AD. One was a very important translational biomarker sub-study conducted at Mount Sinai, and the second was our 52-week monthly and quarterly maintenance dosing data. For alopecia areata, we presented off-treatment data demonstrating strong retention of hair regrowth and additional hair regrowth for patients who received 52 weeks of REZPEG treatment and were followed for six months off treatment. On the heels of this strong EADV presence for REZPEG, we are enrolling patients into our phase III ZENITH-AD program. Our global phase III ZENITH-AD program includes three pivotal studies with 510 patients 12 years or older in each study. All three of these studies have been initiated.
The first ZENITH-AD1 study is evaluating REZPEG monotherapy in patients who are oral JAK inhibitor and biologic naive. For ZENITH-AD2, we have recently made a change to adapt this study to evaluate REZPEG in combination with topical corticosteroids and enroll both naive and experienced patients. This change incorporates recent input from regulatory authorities and is intended to support a label for REZPEG that extends beyond monotherapy to combination use with topical corticosteroids. ZENITH-AD3 is enrolling patients who are JAK inhibitor and biologic experienced. With these three studies enrolling a total of approximately 1,500 patients, we now have a registrational program designed to support the broadest possible label for REZPEG at commercial launch, spanning adults and adolescents, biologic and JAK inhibitor naive and experienced patients, and monotherapy treatment, as well as combination use with topical corticosteroids.
The program positions REZPEG for usage across the full spectrum of patients with moderate to severe atopic dermatitis. As Howard stated, we still expect our initial top-line data in the summer of 2028 from the ZENITH-AD studies, with a goal of filing a BLA by the end of 2029. All three ZENITH-AD studies include a 24-week induction period, with patients receiving REZPEG at 24 micrograms per kilogram every two weeks or placebo. The primary registrational endpoint is an Investigator's Global Assessment, or IGA, at week 24. EASI-75 is a key secondary registrational endpoint and will also serve as a co-primary endpoint with IGA in significant territories outside the U.S. Other important endpoints, which are multiplicity protected in the trials, include itch and patient-reported outcomes, as well as control of comorbid asthma, which affects approximately 25% of patients with moderate to severe AD.
After 24 weeks, patients who achieve an EASI-75 or IGA 0 or one response will enter a 28-week maintenance period evaluating less frequent monthly and quarterly dosing. During induction in the phase IIb REZOLVE-AD trial, REZPEG demonstrated a rapid onset of activity with early improvements in skin clearance and itch and strong efficacy across key clinical endpoints. The longer-term results that were presented again at EADV provided further evidence of REZPEG's potential to deliver durable and deepening disease control. Importantly, both monthly and quarterly maintenance dosing demonstrated sustained responses across key measures of disease activity, including EASI responses, clear or almost clear skin as measured by vIGA, and clinically meaningful itch relief. We also saw new responses emerge in patients who had not achieved these thresholds during induction, with more patients reaching complete skin clearance over time.
As Howard mentioned, we will report the 52-week off-treatment follow-up data from REZOLVE-AD in the first quarter of 2027. As a reminder, we ran an induction treatment and a maintenance treatment in REZOLVE-AD. You will recall that patients who completed the maintenance treatment on REZOLVE had high durability of responses and continuing deepening of responses for endpoints like EASI-75, EASI-90, and EASI-100. Patients who completed the maintenance treatment of 52 weeks entered an off-treatment follow-up period where we continued to evaluate the maintenance of their responses. For these patients who completed 52 weeks on treatment and entered the off-treatment evaluation period, we assessed their maintenance of disease clearance, including EASI and other metrics of disease that are patient-reported, such as itch and quality of life.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
18 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
